PMC:7417114 / 627-1008 JSONTXT

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T5","span":{"begin":70,"end":77},"obj":"http://purl.obolibrary.org/obo/UBERON_0000473"}],"text":"r safety and are more readily available for treatment of patients and testing in clinical trials. Here, we characterize more than 30 approved kinase inhibitors in terms of their antiviral potential, due to their measured potency against key kinases required for viral entry, metabolism, or reproduction. We also highlight inhibitors with potential to reverse pulmonary insufficienc"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T3","span":{"begin":149,"end":159},"obj":"Chemical"},{"id":"T4","span":{"begin":178,"end":187},"obj":"Chemical"},{"id":"T5","span":{"begin":322,"end":332},"obj":"Chemical"}],"attributes":[{"id":"A3","pred":"chebi_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/CHEBI_35222"},{"id":"A4","pred":"chebi_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/CHEBI_22587"},{"id":"A5","pred":"chebi_id","subj":"T5","obj":"http://purl.obolibrary.org/obo/CHEBI_35222"}],"text":"r safety and are more readily available for treatment of patients and testing in clinical trials. Here, we characterize more than 30 approved kinase inhibitors in terms of their antiviral potential, due to their measured potency against key kinases required for viral entry, metabolism, or reproduction. We also highlight inhibitors with potential to reverse pulmonary insufficienc"}

{"project":"LitCovid-PubTator","denotations":[{"id":"12","span":{"begin":57,"end":65},"obj":"Species"}],"attributes":[{"id":"A12","pred":"tao:has_database_id","subj":"12","obj":"Tax:9606"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"r safety and are more readily available for treatment of patients and testing in clinical trials. Here, we characterize more than 30 approved kinase inhibitors in terms of their antiviral potential, due to their measured potency against key kinases required for viral entry, metabolism, or reproduction. We also highlight inhibitors with potential to reverse pulmonary insufficienc"}

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T3","span":{"begin":142,"end":159},"obj":"http://purl.obolibrary.org/obo/GO_0033673"},{"id":"T4","span":{"begin":275,"end":285},"obj":"http://purl.obolibrary.org/obo/GO_0008152"},{"id":"T5","span":{"begin":290,"end":302},"obj":"http://purl.obolibrary.org/obo/GO_0000003"}],"text":"r safety and are more readily available for treatment of patients and testing in clinical trials. Here, we characterize more than 30 approved kinase inhibitors in terms of their antiviral potential, due to their measured potency against key kinases required for viral entry, metabolism, or reproduction. We also highlight inhibitors with potential to reverse pulmonary insufficienc"}

{"project":"LitCovid-sentences","denotations":[{"id":"T6","span":{"begin":98,"end":303},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"r safety and are more readily available for treatment of patients and testing in clinical trials. Here, we characterize more than 30 approved kinase inhibitors in terms of their antiviral potential, due to their measured potency against key kinases required for viral entry, metabolism, or reproduction. We also highlight inhibitors with potential to reverse pulmonary insufficienc"}

{"project":"LitCovid-PMC-OGER-BB","denotations":[{"id":"T12","span":{"begin":149,"end":159},"obj":"CHEBI:35222;CHEBI:35222"},{"id":"T13","span":{"begin":262,"end":267},"obj":"NCBITaxon:10239;GO:0035376"},{"id":"T14","span":{"begin":268,"end":273},"obj":"GO:0035376"},{"id":"T15","span":{"begin":275,"end":285},"obj":"GO:0008152"},{"id":"T16","span":{"begin":290,"end":302},"obj":"GO:0000003"},{"id":"T17","span":{"begin":322,"end":332},"obj":"CHEBI:35222;CHEBI:35222"},{"id":"T18","span":{"begin":359,"end":368},"obj":"UBERON:0002048"},{"id":"T1117","span":{"begin":149,"end":159},"obj":"CHEBI:35222;CHEBI:35222"},{"id":"T74003","span":{"begin":262,"end":267},"obj":"NCBITaxon:10239;GO:0035376"},{"id":"T66167","span":{"begin":268,"end":273},"obj":"GO:0035376"},{"id":"T27260","span":{"begin":275,"end":285},"obj":"GO:0008152"},{"id":"T50531","span":{"begin":290,"end":302},"obj":"GO:0000003"},{"id":"T38108","span":{"begin":322,"end":332},"obj":"CHEBI:35222;CHEBI:35222"},{"id":"T63342","span":{"begin":359,"end":368},"obj":"UBERON:0002048"}],"text":"r safety and are more readily available for treatment of patients and testing in clinical trials. Here, we characterize more than 30 approved kinase inhibitors in terms of their antiviral potential, due to their measured potency against key kinases required for viral entry, metabolism, or reproduction. We also highlight inhibitors with potential to reverse pulmonary insufficienc"}